TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02508168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin hydrochloride 1000 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin hydrochloride 1000 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322MET
Description: SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322MET
Description: SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
Study: NCT03100435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
Study: NCT00640926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radezolid
Description: 300 mg/day, orally for 7-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radezolid
Description: 450 mg/day orally for 7-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radezolid
Description: 900 mg/day orally for 7-10 days
Study: NCT00028925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT02336555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablets
Study: NCT01440751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of ologen Collagen Matrix in trabeculectomy (ologen)
Description: Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
Study: NCT03100435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Fiber Curette
Description: Titanium disks will be decontaminated ex-vivo with carbon fiber curettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Curette
Description: Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
Study: NCT00028925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Study: NCT03567122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Focus of Attention
Description: Information already included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Focus of Attention
Description: Information already included in arm/group descriptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Information already included in arm/group descriptions.
Study: NCT01062906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
Study: NCT03753321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Whey protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: Soy protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: Isoenergetic placebo (maltodextrin) for 10 days (7 days pre-loading and 3 days during trials 1 and 2
Study: NCT03215641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
Study: NCT04784273

Intervention type: PROCEDURE
Intervention: Tibiotalocalcaneal Arthrodesis
Description: Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.

Intervention type: DEVICE
Intervention: DynaNail
Description: Utilization of a novel dynamic compression pseudoelastic intramedullary nail
Study: NCT01440751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Mitomycin-C (MMC) in trabeculectomy
Description: After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
Study: NCT04214444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
Description: The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
Study: NCT01379235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilatis exercise
Description: 12 weeks of pilatis exercise 3 times a week.

Intervention type: OTHER
Group type: OTHER
Intervention: Pilatis exercise
Description: 12 weeks of pilatis exercise 3 times a week.
Study: NCT05455463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online aphasia-adapted physical activity class
Description: Online 50-minute physical activity sessions, two to three times weekly for 10-11 weeks. The activity instructions will be modified to be aphasia-friendly (simplified language, multimodality support).
Study: NCT02114281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not care
Study: NCT04106687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Caudal Block
Description: Postoperative pain procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Caudal Block
Description: Postoperative pain procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral Erector Spinae Block
Description: Postoperative pain procedure
Study: NCT04214444

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
Description: The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
Description: The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
Study: NCT00383565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study: NCT03474601

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue
Study: NCT00698412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cane
Description: This group use the cane every day since the baseline
Study: NCT01408108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
Description: A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic primary posterior crural repair
Description: Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used).
Study: NCT04106687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral Erector Spinae Block
Description: Postoperative pain procedure
Study: NCT02338258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-rotational plate

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exchanged Intramedullary nailing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exchanged Intramedullary nailing
Study: NCT02929290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-9016M
Description: Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day.
Study: NCT04288973

Intervention type: DIAGNOSTIC_TEST
Intervention: Microsoft Kinect Detection during mother child interaction
Description: methodology based on RGB-D sensors applied to the setting of free parent-infant interaction

Intervention type: DIAGNOSTIC_TEST
Intervention: Microsoft Kinect Detection during mother child interaction
Description: methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
Study: NCT03270579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]JNJ-64511070
Description: An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]JNJ-64511070
Description: An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.
Study: NCT01759992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold® Inspiratory Muscle Trainer (treatment).
Description: Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
Study: NCT03282019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy
Description: Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy (HOT)
Description: All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home oxygen therapy (HOT)
Description: All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
Study: NCT02455479

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dAd5GNE Vaccine
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dAd5GNE Vaccine
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dAd5GNE Vaccine
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
Study: NCT02193633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014 3 on/4 off & weekly paclitaxel
Description: AZD2014 3 days on, 4 days off + weekly paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014 2 on/5 off & weekly paclitaxel
Description: AZD2014 2 days on, 5 Days off + weekly paclitaxel
Study: NCT03884231

Intervention type: DEVICE
Intervention: Infinity DBS System with MR Conditional labelling
Description: Patients implanted with the Infinity DBS system with MR Conditional labeling
Study: NCT01005771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GF-001001-00
Description: GF-001001-00 2%, 1% and 0.25% twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GF-001001-00
Description: GF-001001-00 2%, 1% and 0.25% twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GF-001001-00
Description: GF-001001-00 2%, 1% and 0.25% twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02359149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal injections given by a nurse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injections given by a physician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal injections

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF agents
Study: NCT03425136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Description: Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
Study: NCT05365074

Intervention type: DRUG
Intervention: Chloroprocaine Injection
Description: Spinal anesthesia with 50 mg of 1% Chloroprocaine
Study: NCT02903628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye health education
Description: give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
Study: NCT03410485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS index/NoL index
Description: Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variation of baseline mean arterial pressure
Description: Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC.
Study: NCT01968005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoreat®(Etodolac-Lidocaine Topical Patch)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02391220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LCA symbiotic fermented milk
Description: LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: heat-treated fermented milk
Description: heat-treated fermented milk without probiotic cultures and dietary fibres
Study: NCT03674606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Description: One 75 mg aspirin dose taken daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: One 75 mg aspirin dose taken daily
Study: NCT03303274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ipsilateral tilt
Description: The operation table will be tilted 20 degrees right laterally.
Study: NCT03610217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interstitial lung disease induction algorithm
Description: Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
Study: NCT03479879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Estradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol
Study: NCT02341170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HS-PCI
Description: Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
Study: NCT03802799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYN002 - Cannabidiol Transdermal Gel
Description: Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)